Product image of Icalziss (Calcium Chloride Dihydrate) supplied by GNH India

Icalziss

Active Ingredient:
Calcium Chloride Dihydrate
Origin:
EU

Icalziss (Calcium Chloride Dihydrate)

Calcium chloride dihydrate, the active ingredient in Icalziss, is a calcium salt presented as an aqueous solution for extracorporeal use. It supplies calcium ions to restore extracellular calcium concentrations and supports physiological processes that depend on calcium, such as cardiac contractility and coagulation.

GNH India supplies Icalziss as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution. Customers benefit from reliable logistics and responsive technical support throughout the supply chain.

Manufacturer / TM Owner

Vantive Belgium

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Icalziss (calcium chloride dihydrate) is used as an electrolyte supplement in clinical settings that require rapid correction of calcium deficits.

  • Acute hypocalcemia: restores serum calcium levels to prevent neuromuscular and cardiac complications.
  • Hemodialysis procedures: provides calcium to maintain electrolyte balance during extracorporeal circulation.
  • Hyperkalemia management: stabilises cardiac membranes by increasing extracellular calcium concentration.

How It Works

  • Calcium chloride dihydrate dissociates in solution to release calcium ions (Ca2+). The increased extracellular calcium concentration enhances voltage‑gated calcium influx, stabilises cardiac myocyte membranes, supports muscle contraction, and participates in the coagulation cascade. By replenishing calcium stores, it corrects hypocalcaemia and counteracts the membrane‑destabilising effects of hyperkalaemia or calcium‑channel‑blocker toxicity.

Side Effects

Calcium chloride dihydrate may cause a range of adverse reactions when administered intravenously.

Common Side Effects

  • Local irritation or pain at the infusion site.
  • Transient flushing or a metallic taste.
  • Mild hypotension due to vasodilation.
  • Nausea or mild vomiting.
  • Elevated serum calcium (mild hypercalcaemia).

Serious or Rare Side Effects

  • Severe hypercalcaemia leading to cardiac arrhythmias.
  • Tissue necrosis or calcification if the solution extravasates.
  • Life‑threatening cardiac arrest in cases of rapid over‑infusion.
  • Pulmonary edema from fluid overload.
  • Anaphylactoid reactions, though extremely uncommon.

Precautions & Warnings

When using Icalziss, clinicians should observe several safety measures.

  • Renal impairment: monitor serum calcium and renal function closely.
  • Cardiac disease: obtain baseline ECG and watch for arrhythmias.
  • Concomitant digoxin therapy: assess for increased risk of toxicity.
  • Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant.
  • Pediatric patients: adjust dosing and monitor calcium levels carefully.
  • Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Calcium chloride dihydrate can interact with several medications.

Major Interactions (Avoid)

  • Digitalis glycosides: increased risk of digoxin toxicity.
  • Calcium channel blockers: additive cardiovascular effects may cause hypotension.
  • Bisphosphonates: calcium may reduce oral bisphosphonate absorption if given concurrently.

Moderate Interactions (Monitor Closely)

  • Loop diuretics: may increase urinary calcium loss, requiring closer monitoring.
  • Vitamin D analogues: combined use can raise the risk of hypercalcaemia.
  • Magnesium supplements: may alter calcium balance and require serum level checks.

Frequently Asked Questions

Icalziss contains calcium chloride dihydrate and is employed as an intravenous electrolyte supplement to rapidly correct low calcium levels during extracorporeal procedures such as dialysis, to stabilise cardiac membranes in hyperkalaemia, and to support calcium‑dependent physiological functions.

When administered, calcium chloride dihydrate dissociates into calcium ions, raising extracellular calcium concentration. This enhances cardiac membrane stability, supports muscle contraction, participates in the coagulation cascade, and counteracts the effects of elevated potassium or calcium‑channel‑blocker toxicity.

The specific dose of Icalziss is determined by the prescribing clinician based on the patient’s clinical condition, serum calcium level, and the context of use such as dialysis or emergency treatment. Dosage regimens are individualized and not standardized.

Safety data for calcium chloride dihydrate in pregnancy and lactation are limited. It should be used only when the potential therapeutic benefit outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the Icalziss product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Icalziss provides calcium in the form of calcium chloride dihydrate, which delivers calcium ions more rapidly than calcium gluconate or calcium carbonate. This makes it suitable for urgent correction of hypocalcaemia or cardiac stabilisation, whereas oral calcium salts are typically used for chronic supplementation.

Icalziss should be stored below 25 °C in its original packaging, protected from moisture and direct sunlight. The container must be kept sealed until use, and any opened solution should be used promptly according to the manufacturer’s instructions.

Icalziss is administered intravenously under controlled conditions, usually as an infusion or bolus during extracorporeal procedures. The route is extracorporeal use, meaning the solution is added to the circuit of devices such as dialysis machines, following aseptic technique.

The most serious risks include severe hypercalcaemia leading to cardiac arrhythmias, tissue necrosis if the solution extravasates, and life‑threatening cardiac arrest from rapid over‑infusion. Continuous monitoring of serum calcium and cardiac status is essential during administration.

Icalziss should be avoided in patients with known hypersensitivity to calcium chloride, those with severe hypercalcaemia, uncontrolled cardiac arrhythmias, or in situations where rapid calcium elevation could be harmful unless specifically indicated and closely monitored.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Calcium Chloride Dihydrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT